{"id":"botox-purified-neurotoxin-complex","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"drooping eyelid"},{"rate":"1-5%","effect":"facial asymmetry"},{"rate":"1-5%","effect":"headache"},{"rate":"1-5%","effect":"eye pain"},{"rate":"1-5%","effect":"diplopia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in temporary muscle paralysis, which can be used to treat a variety of conditions.","oneSentence":"Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:56:30.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"blepharospasm"},{"name":"strabismus"},{"name":"hemi-facial spasm"},{"name":"cervical dystonia"},{"name":"axillary hyperhidrosis"}]},"trialDetails":[{"nctId":"NCT05216250","phase":"PHASE2","title":"Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-04-12","conditions":"Upper Limb Essential Tremor (UL ET)","enrollment":174},{"nctId":"NCT06218251","phase":"PHASE4","title":"A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-02-05","conditions":"Upper Facial Lines","enrollment":100},{"nctId":"NCT06174688","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-12-12","conditions":"Forehead Lines","enrollment":140},{"nctId":"NCT04949399","phase":"PHASE3","title":"A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-07-08","conditions":"Platysma Prominence","enrollment":408},{"nctId":"NCT04994535","phase":"PHASE3","title":"A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-08-10","conditions":"Platysma Prominence","enrollment":426},{"nctId":"NCT03915067","phase":"PHASE2","title":"BOTOX® for the Treatment of Platysma Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-04-23","conditions":"Platysma Prominence","enrollment":171},{"nctId":"NCT02097121","phase":"PHASE3","title":"OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-05-23","conditions":"Urinary Incontinence, Urinary Bladder, Overactive","enrollment":56},{"nctId":"NCT04631588","phase":"PHASE1","title":"Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2020-11-16","conditions":"Facial Fine Lines","enrollment":172},{"nctId":"NCT01391299","phase":"NA","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-06-01","conditions":"Facial Rhytides, Glabellar Frown Lines","enrollment":175},{"nctId":"NCT02261467","phase":"PHASE3","title":"A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-10-21","conditions":"Forehead Rhytides, Glabellar Rhytides","enrollment":421},{"nctId":"NCT02116361","phase":"PHASE2","title":"OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04-22","conditions":"Depressive Disorder, Major","enrollment":258},{"nctId":"NCT01662492","phase":"PHASE3","title":"A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-10","conditions":"Migraine Disorders","enrollment":125},{"nctId":"NCT02261493","phase":"PHASE3","title":"A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-10-27","conditions":"Facial Rhytides, Glabellar Rhytides","enrollment":787},{"nctId":"NCT02037425","phase":"PHASE4","title":"Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine","status":"COMPLETED","sponsor":"Cady, Roger, M.D.","startDate":"2014-04","conditions":"Chronic Migraine","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Botulinum toxin type A purified neurotoxin complex"],"phase":"phase_2","status":"active","brandName":"BOTOX® purified neurotoxin complex","genericName":"BOTOX® purified neurotoxin complex","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction. Used for blepharospasm, strabismus, hemi-facial spasm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}